-
Dr. Wenyu Shi on Challenges and Strategies for Treating Elderly Patients with DLBCL
From October 18 to 20, 2024, the “2024 Jiangsu Provincial Association of Hematology Physicians Annual Meeting,” hosted by the Jiangsu Provincial Association of Hematology Physicians and organized by Taizhou People’s Hospital and the First Affiliated Hospital of Nanjing Medical University, took place in Taizhou, Jiangsu. This event focused on standardized diagnosis and treatment of hematological…
-
AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma
On October 19, 2024, the 8th Asian Myeloma Network (AMN) Summit was held in Seoul, South Korea. At this event, the International Myeloma Foundation (IMF) hosted the AMN Awards Ceremony. Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, received the AMN Distinguished Achievement Award, recognizing his significant contributions to the field of multiple…
-
IHPBA President Interview | Professor Eduard Jonas: The Transformation of Personalized Hepatocellular Carcinoma Treatment from a Global Perspective
From October 25 to 27, 2024, the 9th Academic Symposium of the International Hepato-Pancreato-Biliary Association China Conference was held in Wuhan. The conference attracted more than 50 internationally renowned experts and scholars from over 20 countries including the United States, Germany, France, Russia, and Australia, as well as 21 academicians from the two academies and…
-
ASH 2024 | Prof. Xiaohui Zhang’s Team Presents 11 Groundbreaking Studies with 3 Oral Presentations！
The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. As the world’s largest and most comprehensive international academic conference in hematology, ASH attracts thousands of experts and scholars from around the globe each year, who come to share cutting-edge developments and breakthrough clinical data.…
-
Overview of Key Updates in the 2024 NCCN Guidelines for Acute Myeloid Leukemia (AML) – First Edition
The latest 2024 NCCN guidelines for Acute Myeloid Leukemia (AML) have been published, presenting significant revisions compared to the 2023, Version 6 update. The new edition brings substantial updates in areas such as intensive induction therapy for AML, post-induction follow-up and reinduction therapy, consolidation, and maintenance treatments.
-
IHPBA President Interview | Professor René Adam: Exploring Innovative Treatments for CRLM
October 21-27, 2024, Wuhan, at the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (IHPBA), we interviewed Professor René Adam, the current President of the IHPBA and a famous surgeon at AP-HP Paul Brousse Hospital in Paris, France, to share his research explorations on the use of liver transplantation combined with…
-
ESMO 2024 | Dr. Dingwei Ye Presents Promising Data on BL-B01D1 for Advanced Urothelial Carcinoma
At the ESMO 2024 Congress in Barcelona, Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented findings from a phase 2 study on BL-B01D1, a novel EGFR and HER3…
-
Dr. Zhiyong Ma: Individualized and Duration-Specific Consolidation Therapy for Lung Cancer Patients
The “Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2024 Edition)” was recently released under the guidance of Academician Jinming Yu from Shandong Cancer Hospital, Professor Ying Cheng from Jilin Cancer Hospital, and Professor Liang’an Chen from the Chinese PLA General Hospital. This consensus provides evidence and guidance for the application of…
Connecting Medical Expertise through Media